Home Arena Pharmaceuticals Announces BELVIQ (lorcaserin HCl) New Drug Submission In Canada
 

Keywords :   


Arena Pharmaceuticals Announces BELVIQ (lorcaserin HCl) New Drug Submission In Canada

2013-07-03 06:56:53| drugdiscoveryonline News Articles

Arena Pharmaceuticals, Inc.announced recently that Eisai Limited (based inMississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission (NDS) for BELVIQ™ (lorcaserin HCl) with Health Canada

Tags: canada drug submission arena

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
01.07Hurricane Beryl Update Statement
01.07Summary for Hurricane Beryl (AT2/AL022024)
01.07BASFs TECH Academy Introduces Louisiana High School Students to Technical Careers
01.07Comericas Patterson Helps Entrepreneurs Grow Their Waste and Recycling Businesses
01.07Hitachi Zosen Inova Acquires Babcock & Wilcox's Denmark-Based Renewable Parts and Services Subsidiary
01.07Hurricane Beryl Graphics
01.07Hurricane Beryl Public Advisory Number 11A
01.07Summary for Hurricane Beryl (AT2/AL022024)
More »